Dexcom's Kevin R. Sayer plans $2.4M stock sale

Rhea-AI Filing Summary

DEXCOM, INC. (DXCM) received a Rule 144 notice from Kevin R. Sayer covering a proposed sale of 26,756 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $2,408,240.67 and an anticipated sale date of 08/20/2026. The shares derive from restricted stock acquired from the issuer on 01/28/2025. The notice also lists prior sales over the past three months.

Key Figures

Shares proposed to be sold: 26,756 shares Aggregate market value of proposed sale: $2,408,240.67 Shares outstanding: 377,360,765 shares +5 more

8 metrics

Shares proposed to be sold 26,756 shares Common stock to be sold through Morgan Stanley Smith Barney LLC

Aggregate market value of proposed sale $2,408,240.67 Value associated with 26,756 shares of Dexcom common stock

Shares outstanding 377,360,765 shares Dexcom common shares outstanding cited in the notice

Prior sale on 07/20/2026 26,756 shares for $2,041,999.19 Common stock sold by Kevin R. Sayer during the past three months

Prior sale on 07/06/2026 26,756 shares for $1,926,432.00 Common stock sold by Kevin R. Sayer during the past three months

Prior sale on 05/21/2026 26,759 shares for $1,926,648.00 Common stock sold by Kevin R. Sayer during the past three months

Acquisition date of restricted stock 01/28/2025 Date restricted stock from the issuer was acquired

Approximate date of sale 08/20/2026 Anticipated date for the proposed Rule 144 sale

Key Terms

Rule 144, Restricted Stock, aggregate market value, securities to be sold, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock financial

"Common | 01/28/2025 | Restricted Stock | Issuer"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

aggregate market value financial

"Common ... | 26756 | 2408240.67 | 377360765 | 08/20/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

securities to be sold financial

"144: Securities To Be Sold"

Securities Sold During The Past 3 Months financial

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for DXCM disclose about Kevin R. Sayer's planned sale?

The notice states that 26,756 shares of Dexcom common stock may be sold for an aggregate market value of $2,408,240.67 through Morgan Stanley Smith Barney LLC, with an anticipated sale date of 08/20/2026, under Rule 144.

How many DXCM shares has Kevin R. Sayer sold in the past three months?

The notice lists three sales: 26,756 shares on 07/20/2026 for $2,041,999.19, 26,756 shares on 07/06/2026 for $1,926,432.00, and 26,759 shares on 05/21/2026 for $1,926,648.00.

What is the origin of the DXCM shares covered by this Form 144?

The shares are described as Common stock received as Restricted Stock from the Issuer, acquired on 01/28/2025. These restricted shares are the securities proposed to be sold under Rule 144.

Which broker is handling the proposed DXCM share sale under this Form 144?

The proposed sale is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, based at 1 New York Plaza, 8th Floor, New York, NY 10004, in connection with Dexcom common stock traded on NASDAQ.

What number of DXCM shares outstanding is cited in the Form 144 notice?

The notice cites 377,360,765 shares of Dexcom common stock as outstanding in the same table that lists the proposed sale of 26,756 shares and their $2,408,240.67 aggregate market value.

Who signed the DXCM Form 144 and when?

The notice is signed by /s/ Kevin R. Sayer. The document shows the date 08/20/2026 in the remarks and signature section, indicating when the notice was executed in connection with the planned sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 04:49 PM Accepted by SEC EDGAR 08/20/2026 - 04:49 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001286858
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DEXCOM, INC.
SEC File Number	000-51222
Address of Issuer	6340 Sequence Drive San Diego CALIFORNIA 92121
Phone	(858) 200-0200
Name of Person for Whose Account the Securities are To Be Sold	KEVIN R SAYER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	26756	2408240.67	377360765	08/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/28/2025	Restricted Stock	Issuer			26756	01/28/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
KEVIN R SAYER 6340 Sequence Drive San Diego CA 92121	Common	07/20/2026	26756	2041999.19
KEVIN R SAYER 6340 Sequence Drive San Diego CA 92121	Common	07/06/2026	26756	1926432.00
KEVIN R SAYER 6340 Sequence Drive San Diego CA 92121	Common	05/21/2026	26759	1926648.00

144: Remarks and Signature

Remarks
Date of Notice	08/20/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kevin R Sayer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)